Advaxis Inc. (ADXS) Shares Down 3.4%
Advaxis Inc. (NASDAQ:ADXS) shares dropped 3.4% during trading on Thursday . The company traded as low as $12.86 and last traded at $13.22, with a volume of 3,076,919 shares traded. The stock had previously closed at $13.69.
ADXS has been the topic of several research analyst reports. Jefferies Group reaffirmed a “buy” rating on shares of Advaxis in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Advaxis in a research note on Friday. Barclays PLC raised their price objective on Advaxis from $15.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Advaxis in a research note on Tuesday, May 17th. Six research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus target price of $25.80.
The stock’s market cap is $489.77 million. The company’s 50 day moving average price is $8.71 and its 200 day moving average price is $8.13.
In other news, Director Thomas J. Mckearn sold 4,100 shares of the company’s stock in a transaction on Friday, May 13th. The stock was sold at an average price of $7.45, for a total transaction of $30,545.00. Following the transaction, the director now owns 82,120 shares of the company’s stock, valued at approximately $611,794. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Advaxis, Inc is a clinical-stage biotechnology company. The Company’s immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm or Listeria) bioengineered to secrete antigen/adjuvant fusion proteins. It is focused on the discovery, development and commercialization of Lm-LLO cancer immunotherapies.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.